Authors
Latest:
COVID-19: A New Era for Clinical Trial Research in Europe?A look at the issues in Europe affecting ongoing trials including data management, measures being taken by sponsors, and more.
Latest:
Implementing ePROs in Arthritis Clinical ResearchThe value of electronic patient-reported outcomes data in this disease setting.
Latest:
5 Strategies for Bridging the Sponsor-Site Tech DivideResults from survey of 100 site personnel suggest a disconnect is present between these stakeholders.
Latest:
Africa is Biosimulation’s Next FrontierThe answers to meeting biosimulation's growing demand for talent may lie in Africa.
Latest:
Regulatory CMC: Enhancing Biologics DevelopmentPreventing delays and accelerating the progression of these critical therapies.
Latest:
Using Digital Technology to Empower Patients and Restore TrustLooking at the road ahead to properly utilizing digital technology in clinical trials.
Latest:
The Impact of Decentralized and Hybrid Trials on Sponsor and CRO CollaborationsTufts CSDD study in collaboration with ten biopharmaceutical organizations and CROs examines sponsor/CRO relationships.
Latest:
COPD: Therapies on the CuspClinical trials in this area reflect new science, and corresponding challenges in their execution.
Latest:
Beyond the Black Box: Tailoring AI Regulation in HealthcareAs adoption increases, regulatory bodies are becoming more involved in the oversight of artificial intelligence.
Latest:
A Digital Twin on CAR-T Cytokine Release Syndrome (CRS) Patients with Standard of Care Measured by CRS Distribution by GradeUsing existing clinical trial data to proactively model patient safety and efficacy outcomes could aid in accelerating development for areas in need of new therapies.
Latest:
Evolving Tools and Perspectives for the Development of Cell and Gene TherapiesStakeholders must alter their mindsets when it comes to early-phase design and interpreting regulatory guidance for CGT trials.
Latest:
Applied AI and Advanced Automation in Clinical TrialsUse cases spotlight the growing potential of generative AI in the CRO space.
Latest:
Streamlining Clinical Trials with eSource: Insights from MSKA use case by Memorial Sloan Kettering Cancer Center explores the potential of EHR-to-EDC.
Latest:
Self-collection of Blood Specimens in Clinical TrialsOperational and patient burden considerations for self-collection of blood specimens in clinical trials
Latest:
Cancer Won’t Wait for COVID to End: Conducting Trials Amid the Coronavirus PandemicThousands of trials have been halted as a consequence of the coronavirus pandemic, slowing the pace of scientific progress dramatically.
Latest:
5 Reasons Physicians Should Integrate Clinical Trials Into Their PracticeUsing IROs can offer the opportunity for doctors to incorporate clinical research as a care option in their practices.
Latest:
Streamlining Clinical Trials: Mitigation and ManagementHow service providers are helping to accelerate drug development.
Latest:
At-home Self-collection of Blood Specimens for Safety Lab Testing in Clinical Trials via the Tasso+ DeviceLaboratory services organization focuses on easing patient and site burden with improved collection device.
Latest:
What Do COVID-19 Vaccine Timelines Mean For Clinical Development?The pandemic spurred an urgency to innovate that improved clinical development in ways that should benefit the industry beyond COVID-19.
Latest:
Towards a Global Implementation of eConsent in Clinical TrialsAll stakeholders must play part in increasing implementation.
Latest:
Creating Strategic Relationships: The Changing Face of Contract Research Organizations and Sponsor PartnershipsBy taking on tasks such as clinical trial management, logistics, statistics, and data management, contract research organizations have helped expand the capabilities of their sponsor partners and accelerate drug development timelines.
Latest:
Helping Rescued Adjudication Committees Get Back on TrackDetermining if an EAC is at risk and key actions to mitigate trial impact.
Latest:
Where Innovation and Patients Meet to Improve Cancer CarePromising scientific advances are pacing oncology drug development.
Latest:
Master Protocols: Implementing Effective Treatment Adaptations in the RandomizationIt is unrealistic to include infinite adaptations in an IRT system, thus identifying the optimal level of adaptations requires examination of the study’s characteristics and planning phase considerations.
